Latest VivoSim Labs News & Updates

See the latest news and media coverage for VivoSim. We track all announcements, press releases, and industry mentions in real time, all in one place.

VivoSim Labs (VivoSim)

Human-relevant 3D liver and intestinal toxicology model developer

Last updated Today

Latest news about VivoSim Labs (VivoSim)

In short: VivoSim regained Nasdaq compliance, secured $6 million from Eli Lilly, and launched its first commercial testing services in China.

August 6 VivoSim

Received $5 million milestone and $1 million escrow release from Eli Lilly, completed $4 million financing, and holds $10.1 million cash.

July 21 VivoSim

The two initial engagements with Chinese pharma companies mark a milestone in Asia-Pacific expansion and validate channel strategy.

July 16 VivoSim

The placement is with a single healthcare-focused institutional investor and includes warrants exercisable at $0.85 per share.

July 15 VivoSim

The milestone triggers upon Phase 2 patient dosing. VivoSim is eligible for up to $45 million additional payments.

August 12 Houston Chronicle

Options data delayed by 15 minutes. For real-time data, try AlphaSpace .

Never miss news about VivoSim

Track VivoSim and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Discover what's making headlines across other trending companies.